Travis Alvin Thompson Sells 1,750 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson sold 1,750 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $24,657.50. Following the completion of the sale, the chief accounting officer now directly owns 34,991 shares of the company’s stock, valued at $493,023.19. This trade represents a 4.76 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Travis Alvin Thompson also recently made the following trade(s):

• On Monday, January 6th, Travis Alvin Thompson sold 2,686 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $15.00, for a total transaction of $40,290.00.
• On Monday, November 11th, Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $25.11, for a total value of $157,088.16.

Bicycle Therapeutics Trading Down 6.4 %

Shares of Bicycle Therapeutics stock opened at $14.17 on Thursday. Bicycle Therapeutics plc has a 12-month low of $12.17 and a 12-month high of $28.67. The company has a market cap of $978.38 million, a P/E ratio of -4.31 and a beta of 0.92. The company’s fifty day simple moving average is $19.09 and its two-hundred day simple moving average is $21.82.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $6.82 million. During the same quarter in the previous year, the company earned ($1.26) earnings per share. Bicycle Therapeutics’s quarterly revenue was down 50.0% on a year-over-year basis. Analysts predict that Bicycle Therapeutics plc will post -3.05 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a research note on Friday, November 1st. HC Wainwright lowered their price objective on Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a research report on Monday, December 16th. JMP Securities cut their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. Stephens initiated coverage on shares of Bicycle Therapeutics in a report on Friday, November 8th. They set an “equal weight” rating and a $25.00 price target for the company. Finally, B. Riley dropped their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.25.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in BCYC. Assetmark Inc. bought a new stake in shares of Bicycle Therapeutics during the third quarter valued at approximately $34,000. GAMMA Investing LLC lifted its position in Bicycle Therapeutics by 105.1% during the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after buying an additional 1,038 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Bicycle Therapeutics by 69.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after buying an additional 2,918 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after buying an additional 1,782 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth about $206,000. Institutional investors own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.